Positive results from drug trials could boost Seattle Genetics' shares

08/20/2010 | Reuters

Positive results from clinical trials of Seattle Genetics' drug candidates for leukemia and lymphoma could make 2010 a milestone year for the biotech company, according to this Reuters analysis. The biotech firm is expected to reveal study data of lintuzumab, a treatment for acute myeloid leukemia, between later this month and October and brentuximab vedotin, a Hodgkin lymphoma drug, by late September.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC